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Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in
blood plasma DNA. Concentration of cirDNA and methylation of RARb2, RASSF1A and HIC-1 gene promoters were investigated in
cell-free and cell-surface-bound fractions from healthy donors, patients with breast cancer, and patients with breast fibroadenoma.
Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-
bound fractions. Analysis of RARb2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer
patients, 60% in patients with benign lesions, and is without false-positive results in healthy women. Results of the study indicate that
methylation-specific PCR of RARb2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of
cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and
discrimination of malignant and benign breast tumours.
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In the last years attempts have been made to develop noninvasive
tests for early cancer diagnostics based on analysis of extracellular
DNA circulating (cirDNA) in the blood. The increased plasma
cirDNA concentration itself can be an indication of tumour
development (Anker, 2000). However, this test did not promise to
be specific, as far as the comparable increase of DNA concentra-
tion in plasma was found in patients with other disorders as
systemic lupus erythematosus, rheumatoid arthritis, glomerulone-
phritis, pancreatitis, hepatitis, etc (Anker, 2000).
Numerous studies have demonstrated tumour-specific altera-
tions, such as aberrant promoter hypermethylation in cirDNA
recovered from plasma of patients with different malignancies, and
the absence of methylated DNA in healthy persons (Silva et al,
2002). Changes in the status of DNA methylation represent one of
the most common molecular alterations in human neoplasia
(Egger et al, 2004), including breast cancer (Widschwendter and
Jones, 2002). These epigenetic alterations induce neoplastic
process by transcriptional silencing of tumour suppressor gene
expression and are responsible for initial steps of induction of
tumour cell proliferation (Jones and Baylin, 2002). Therefore,
analysis of gene methylation patterns in tissues could be of
profound significance in the early detection of cancer (Esteller
et al, 2001). Expression of more than 40 genes was found to be lost
in breast cancer because of promoter hypermethylation (Jones and
Baylin, 2002; Widschwendter and Jones, 2002), including RASS-
F1A, RARb2, HIC-1 genes. However, the methylated markers are
detected with twice lower frequency in plasma samples compared
with the frequency of their finding in the tissues of cancer patient
(Shao and Nguyen, 2002; Anker P et al, 2003). According to our
recent observations, extracellular nucleic acids circulate in blood
not only in plasma but are also bound to the surface of blood cells
(Rykova et al, 2004). In pilot experiments we evaluated the cell-
surface-bound cirDNA as a source of material for the early breast
cancer diagnostics based on methylation-specific PCR (MSP)
(Rykova et al, 2004). In the present study we investigated the
methylation of HIC-1, RASSF1A and RARb2 genes promoters in
cirDNA derived from plasma and cell-surface-bound fractions of
patients with breast tumours.
Results of the study evidence that the analysis of the cell-
surface-bound cirDNA along with cirDNA from plasma fraction
could considerably increase reliability of noninvasive tests for
tumour development based on MSP.
MATERIALS AND METHODS
Blood samples
Blood samples of previously untreated breast cancer and
nonmalignant patients were obtained from Novosibirsk Regional
Oncology Dispensary. The Ethics Committee in Dispensary
approved specimen collection procedures. Tumour staging was
performed according to the TNM classification. Blood samples of
healthy donors, selected for blood transfusion, were obtained from
Novosibirsk Central Clinical Hospital. Blood (8ml) was collected
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sinto the tubes containing 2ml of sterile phosphate-buffered saline
(PBS) with 50mM EDTA. Blood was fractionated into plasma,
leucocytes and erythrocytes, and cell-surface-bound DNA fractions
were obtained as described earlier (Rykova et al, 2004).
DNA extraction and concentration measurement
DNA was extracted from 1ml of plasma samples, 2ml of PBS/
EDTA samples and 1ml of trypsin samples by glass milk-based
protocol providing quantitative isolation of DNA (Tamkovich et al,
2004). Concentration of DNA was measured using Hoechst 33258
assay (Labarca and Paigen, 1980). Detection limit for DNA
calculated to the initial blood volume was 8ngml
 1 in plasma,
20ngml
 1 in trypsin eluates and 40ngml
 1 in PBS/EDTA eluates.
Methylation-specific PCR
Aberrant methylation of RASSF1A, RARb2 and HIC-1 gene
promoters was determined by MSP according to modified protocol
(Herman et al, 1996). DNA was extracted from 1ml of plasma
samples, 6ml of PBS-EDTA samples and 1ml of trypsin samples by
glass milk-based protocol (Tamkovich et al, 2004). Isolated DNA
was modified by sodium bisulfite, purified using glass milk
protocol, eluted into 30ml of water and stored in aliquots at  401C.
A volume of 3ml of the bisulfite-modified DNA was used in MSP
reaction. The primers used are listed in Table 1. Polymerase chain
reaction products were visualised on 6% PAAG stained with
ethidium bromide.
RESULTS
We analysed concentrations of cell-surface-bound and cell-free
cirDNA in the blood samples of 20 breast cancer patients, 15
patients with nonmalignant tumour (fibroadenoma) and 10
healthy women. Analysis of the distribution of cirDNA in blood
of breast cancer patients supports our earlier data (Laktionov et al,
2004) that the main part of the cirDNA in the blood of healthy
donors is absorbed at the surface of blood cells (Figure 1). A strong
decrease of the cell-surface-bound cirDNA amount, as well as an
increase of cell-free cirDNA was found in cancer relative to health
(Figure 1). In the blood of 95% of breast cancer patients, increased
amounts of cirDNA were found in plasma and only negligible
amounts of cell-surface-bound cirDNA were found in few patients
of this group. Patients with fibroadenoma were characterised by
increased level of circulating DNA in plasma similar to cancer
patients, albeit cirDNA were found also at the surface of blood cells
similar to what was found in healthy women (Figure 1).
Methylation of RASSF1A, RARb2 and HIC-1 gene promoters
were studied in healthy donors and patients with breast tumours.
These genes had been reported to be frequently methylated in
breast cancer (Esteller et al, 2001; Jones and Baylin, 2002;
Widschwendter and Jones, 2002). CirDNA isolated from the
plasma of 10 healthy women were found to be negative for
methylation forms of all three genes. Methylation of RARb2 and
RASSF1A promoters was not found in the cirDNA isolated from
cell-surface-bound fractions, whereas five healthy women out of
ten were positive for methylated HIC-1 in different cell-associated
cirDNA fractions (Table 2). Methylated form of RASSF1A gene was
detected with the same frequency (60%) in the cell-bound cirDNA
from patients with cancer and nonmalignant breast tumours
(Table 2). In contrast, methylated RARb2 form was detected three
times more frequently in breast cancer patients than in
fibroadenoma patients: in 60% of cell-associated cirDNA in cancer
and 20% in nonmalignant cases (Table 2). The methylation of all
three genes was detected considerably more frequently in the cell-
bound cirDNA than in the plasma cirDNA of the tumour-bearing
patients (Table 2). The methylation pattern of the different genes
differ among patients; some patients demonstrated simultaneous
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Figure 1 Concentrations of circulating DNA in plasma (Plasma) and cell-
surface-bound DNA (CSB) in blood of healthy women (Health), breast
cancer patients (Cancer) and patients with breast fibroadenoma (Fibroade-
noma).
Table 1 Sequences of primers used in MSP
Gene Primer sequence (50–30)
Genbank
accession no.
Amplicon location
(Genebank numbering) T (in 1C)
Length
(in bp)
RASSF1A Mf: GGG TTT TGC GAG AGC GCG 169
Mr: GCT AAC AAA CGC GAA CCG AC002481 17881–18115 64
Uf: GGT TTT GTG AGA GTG TGT TTAG 59 169
Ur: CAC TAA CAA ACA CAA ACC AAG
RARb2 Mf: GCT TAG TAG TTC GGG TAG GGT TTA TC 235
Mr: CCG AAT CCT ACC CCG ACG X56849 773–1007 64
Uf: TTA GTA GTT TGG GTA GGG TTT ATT 55 233
Ur: CCA AAT CCT ACC CCA ACA
HIC-1 Mf: TCG GTT TTC GCG TTT TGT TCG T 95
Mr: AAC CGA AAA CTA TCA ACC CTC G L41919 26–120 64
Uf: TTG GGT TTG GTT TTT GTG TTT TG 64 118
Ur: CAC CCT AAC ACC ACC CTA AC
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smethylation of RARb2 and RASSF1A, while some of them were
positive only in either RARb2 or RASSF1A regions. To summarise,
two methylated markers RARb2 and RASSF1A were not found in
healthy women but were detected in 95% of the cancer patients and
in 60% of the patients with fibroadenoma when total circulating
DNA were used for MSP reaction (Table 2).
DISCUSSION
CirDNA is present in blood plasma in health and is increased in
cancer and other malignancies (Anker, 2000). These findings have
attracted much attention to the potential use of elevated
concentration of cirDNA as a tumour marker. It is known that
nucleic acids can bind with cell-surface DNA-binding proteins
(Bennett et al, 1985; Laktionov et al, 1999), as well as
with phospholipids of cellular membrane through bivalent ions
(Beliaev et al, 1988). These interactions together with large amount
of cells in the bloodstream provide an opportunity for circulation
of DNA in blood being absorbed at cell surface. Earlier we
have found that a fraction of the bound nucleic acids could be
detached from the cell surface by PBS/EDTA treatment suggesting
involvement of bivalent ions in the complex formation.
Further removal of the surface-bound cirDNA can be achieved
by mild trypsin treatment, which destroys cell surface proteins
binding with cirDNA. In accordance with previous data (Laktionov
et al, 2004) results of the present study indicate that the main part
of the cirDNA in the blood of healthy donors is mainly absorbed at
the surface of blood cells (Table 2). Our data demonstrate
redistribution of extracellular DNA in blood between cell surface
and plasma in breast tumour-bearing patients, which suggest a
possibility of the development of simple noninvasive tumour-
screening assay.
Mechanisms regulating appearance and distribution of extra-
cellular DNA in blood are not clear to date. In the bloodstream
extracellular DNA are under the pressure of factors influencing its
circulation and clearance, including hydrolysing enzymes. It is
known that tumour invasion in cancer patients is accompanied by
increased level of proteases (Farias et al, 2000). Damage of the cell-
surface DNA-binding proteins by these enzymes can result in
detachment of cell-bound DNA. Cancer development is charac-
terised by the change of DNase activity in blood plasma. It was
shown recently, that the decreased DNase activity in plasma of
patients with gastrointestinal cancer correlates with the increased
integrity of cirDNA and their concentration in blood plasma
(Tamkovich et al, 2006). Other factors should be further
investigated, which could influence extracellular DNA distribution
in the circulation in health and in the process of tumour
development.
Tumour-related methylated forms of three genes (RARb2,
RASSF1A and HIC-1) were much more frequently evaluated in
the cell-surface-bound cirDNA compared with cell-free cirDNA in
tumour-bearing patients (Table 2). The data obtained clearly
indicate that cell-surface-bound DNA provides valuable source of
material for MSP diagnostics along with cirDNA isolated from the
plasma. According to our data RARb2 gene methylation possesses
the most cancer-specific propensity. In contrast, methylation of
HIC-1 promoter region, which was examined here, is not tumour
specific.
Analysis of methylated DNA sequences in the cirDNA
demonstrated no regularities in their fraction distribution
(Table 2). Phosphate-buffered saline and trypsin treatments
both provide cell-bound DNA, which should be used combined
as a template for the MSP-based assay. There is no significant
difference in the methylation frequencies for the leucocyte-
bound cirDNA compared with erythrocyte-bound cirDNA,
when any of three genes was analysed. However, as long as there
are 1000 times less leucocytes than erythrocytes in blood, we
propose that specific content of methylated DNA at the surface of a
single leucocyte is higher than at the surface of a single
erythrocyte.
Whatever might be the mechanism for tumour-related DNA
binding to blood cells, we can now ask whether this phenomenon
has potentially important implications in cancer patients.
Experiments with human fibroblasts provided evidences that
tumour DNA may be horizontally transferred by the uptake
of apoptotic bodies (Holmgren et al, 1999). Garcia-Olmo et al
(1999)suggested that metastases might develop as a result of
transfection of susceptible cells in distant target organs
with dominant oncogenes that circulate in plasma and are derived
from the primary tumour. Monocyte cells from leucocyte fraction,
which can migrate into the tissues from the blood vessels, could
play the role of ‘carriers’ of the surface-bound tumour DNA to
healthy cells.
Our data indicate the presence of methylated RASSF1A and
RARb2 in the cirDNA of all the detected patients bearing the Ist
Table 2 Frequency of methylation of RASSF1A, RARb and HIC-1 genes in plasma and cell-surface-bound DNA in blood of breast cancer patients,
patients with fibroadenoma and healthy donors
Erythrocytes Leucocytes
Diagnosis Gene Plasma
PBS
eluate
Trypsin
eluate
PBS
eluate
Trypsin
eluate
Total cell-surf-
bound
Plasma and total
cell-surf-bound
Breast cancer (n¼20) HIC-1 55* 35 45 70 45 90 90
RASSF1A 15 35 0 35 30 65 75
RARb2 15 5 25 20 15 60 65
RASSF1A or RARb2 30** 95
Fibroadenoma (n¼15) HIC-1 40 27 73 67 53 93 93
RASSF1A 7 27 33 40 27 53 53
RARb2 13 0 7 0 13 20 33
RASSF1A or RARb21 3 60
Healthy donors (n¼10) HIC-1 0 10 10 50 20 50 50
RASSF1A 0 0 0 0 0 0 0
RARb2 00000 0 0
RASSF1A or RARb20 0
*Percentage of cases with RASSF1A, RARb2, HIC-1 hypermethylation in plasma DNA, cell-surface bound DNA and total circulating DNA.
**Percentage of cases with RASSF1A or RARb2 hypermethylation in plasma DNA and total circulating DNA.
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stumour stage. This sounds optimistic for the development of
tumour-specific screening test, taking into account the early stage
of these changes to occur. To summarise, assay based on the
methylated RARb2 or RASSF1A detection in the total circulating
DNA in blood provides 95% sensitivity for breast cancer detection.
Additional quantitative analysis of the distribution of extracellular
DNA between cell-bound and cell-free fractions in blood is helpful
to differentiate healthy women, patients with breast fibroadenoma
and breast cancer patients.
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